Major Prescription Drug Categories in India

India regulates prescription medicines through a layered legal framework that controls how drugs are manufactured, sold, stored and dispensed. The system distinguishes between different categories of medicines based on their therapeutic use and risk profile, with stricter controls for drugs that can cause misuse, dependence or public health harm.

Legal framework for drug control

The main law governing drugs in India is the Drugs and Cosmetics Act, 1940. It provides the legal foundation for regulating the import, manufacture, distribution and sale of drugs and cosmetics. The Act is operationalised through the Drugs Rules, 1945, which lay down detailed conditions for licensing, storage, sale and dispensing.

Within these rules, Rule 65 is especially important for prescription medicines because it specifies the conditions for granting sale licences and for operating premises used for retail and wholesale drug business. In practice, this framework seeks to ensure that medicines remain safe, effective and available only through lawful channels.

Schedule H: prescription medicines for supervised use

Schedule H drugs are prescription medicines that can be sold only on the prescription of a Registered Medical Practitioner (RMP). These medicines cover a wide range of therapeutic categories and are not meant for over-the-counter sale without medical advice.

• Prescription requirement: Sale is permitted only against a valid prescription from an RMP.
• Public safety role: The schedule helps reduce self-medication and ensures diagnosis before treatment.
• Medical supervision: It supports proper monitoring of treatment and adverse drug reactions.
• Rational drug use: The category encourages use of medicines only when clinically justified.
• Common exam angle: Schedule H is the broad, standard prescription category under the Drugs Rules, 1945.

Schedule H1: tighter control on selected medicines

Schedule H1 was introduced for stricter regulation of selected medicines that require closer monitoring. It includes certain antibiotics, anti-tuberculosis medicines and specific habit-forming drugs. Compared to Schedule H, it places greater responsibility on pharmacists and retailers to maintain records and prevent misuse.

• Targeted medicines: Selected antibiotics, anti-TB drugs and certain habit-forming medicines.
• Stricter record-keeping: Sale details must be maintained carefully.
• Record particulars: The prescriber’s name, patient’s name and address, quantity supplied and date of dispensing are recorded.
• Antibiotic stewardship: The category supports control of antibiotic misuse and helps address antimicrobial resistance.
• Misuse prevention: It also limits abuse of potentially dependence-producing medicines.
• Exam significance: Schedule H1 is stricter than Schedule H but less restrictive than Schedule X.

High-yield fact: Schedule H1 is meant to improve accountability in dispensing, especially for antibiotics and other medicines where misuse has wider public health consequences.

A later amendment in July 2026 brought medicinal products containing more than 12 per cent v/v ethyl alcohol, when supplied in quantities exceeding 30 mL, under Schedule H1. These products were made prescription-based to strengthen control over their sale.

Schedule X: the most stringent controls

Schedule X drugs include narcotic and psychotropic medicines that are subject to the strictest controls under the Drugs and Cosmetics Rules. Because of their potential for abuse, diversion and illicit trafficking, they are regulated more tightly than ordinary prescription medicines.

• Highest level of control: Sale, storage and record-keeping are tightly regulated.
• Special licence: Stocking and selling Schedule X medicines requires specific authorisation.
• Secure storage: These medicines must be kept in secure facilities.
• Transaction records: Detailed records of purchase and sale are mandatory.
• Audit and inspection: Records are subject to scrutiny by regulatory authorities.
• Medical purpose only: The schedule is intended to ensure legitimate clinical use and prevent diversion.

Regulatory bodies and rule-making process

Drug regulation in India is supported by advisory and consultative bodies that help maintain uniform standards across the country. The Drugs Technical Advisory Board (DTAB) is the apex statutory body on technical matters related to the administration of the Act. It advises both the Central and State Governments on matters requiring expert input.

The Drugs Consultative Committee (DCC) works to ensure uniformity in the implementation of the law across India. It advises the Central Government, State Governments and the DTAB. In practice, proposals for changes in drug regulation are examined through these bodies before the Ministry of Health and Family Welfare issues final notifications.

• DTAB: Apex statutory advisory body on technical questions under the Act.
• DCC: Advises on uniform application of drug laws across the country.
• Policy process: Draft changes are examined, recommended and then notified by the Ministry.
• Administrative role: These bodies help balance patient safety, access and enforcement.
• Regulatory significance: They are central to interpreting and updating drug-control measures.

Key Prelims Takeaways

• Primary law: The Drugs and Cosmetics Act, 1940 is the main law regulating drugs in India.
• Rules under the Act: The Drugs Rules, 1945 were framed under the Act.
• Rule 65: It lays down conditions for drug sale licences and premises.
• Schedule H: These medicines require a prescription from a Registered Medical Practitioner.
• Schedule H1: It covers selected antibiotics, anti-TB medicines and certain habit-forming drugs, with stricter records than Schedule H.
• Schedule X: These are narcotic and psychotropic medicines with the strictest controls on sale and storage.
• DTAB and DCC: The DTAB is the apex technical advisory body, while the DCC promotes uniform implementation of drug laws.

Recent Context

On September 8, 2026, the Union Health Ministry issued a draft notification proposing amendments to Rule 65 of the Drugs Rules, 1945. The draft requires CCTV surveillance at medical premises, excluding wholesale dealers, that supply prescription medicines, with recordings to be preserved for at least three months. Public objections and suggestions have been invited.